CCN2 and arthritic joint disease: A study by Nozawa et al. showed that anti-CTGF mAb treatment prevented the progression of arthritis in collagen-induced arthritis (CIA) mice through the suppressive effects on T cell proliferation and Th17 differentiation, indicating that CTGF may become a new target for the treatment of RA [16].